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Percutaneous repair of abdominal aortic aneurysm
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Eskandari, MD, Jon S. Matsumura, MD, and William H. Pearce, MD, Chicago, Ill
Objective: Percutaneous treatment of an abdominal aortic aneurysm (AAA) is feasible, but is associated with a unique set
of risks. A comparison of Excluder endograft deployment with femoral artery cutdown (FAC) versus percutaneous
femoral access (PFA) for treatment of infrarenal AAA was undertaken.
Methods: A single-institution, controlled, retrospective review was carried out in patients who underwent either bilateral
FAC or bilateral PFA for endovascular repair of infrarenal AAA with the Gore bifurcated Excluder endograft between
March 1999 and November 2003. To November 2000, 35 patients underwent bilateral FAC; since then, 47 patients have
undergone bilateral PFA. All have been followed up for at least 30 days.
Results: Mean AAA size was 5.7 cm in the FAC group and 6.0 cm in the PFA group. During hospitalization there were
six access-related complications in the FAC group; three required early surgical intervention. In the PFA group nine
perioperative access-related complications occurred, all consisting of either hemorrhage or arterial occlusion; seven
required additional intervention, and were recognized and ameliorated while the patient was still in the operating room.
At 30-day follow-up there were no additional access-related complications in the PFA group. There were eight other
access-related complications in eight additional patients who underwent FAC. In patients undergoing bilateral PFA total
operative time was shorter (PFA 139 minutes vs FAC 169 minutes; P .002), total in-room anesthesia time was less (PFA
201 minutes vs FAC 225 minutes; P < .008), and use of general anesthesia was reduced (P < .001). No significant
differences were observed between groups with respect to estimated blood loss (PFA 459 mL vs FAC 389 mL; P .851).
Conclusion: Complete percutaneous treatment of AAA may have some advantages over open femoral artery access, but it
is not free from risk. Percutaneous treatment of AAA can be completed successfully in most patients, but should be
performed at an institution where conversion to an open procedure can be completed expeditiously if necessary. (J Vasc
Surg 2004;40:12-6.)With Food and Drug Administration approval, en-
dograft repair of abdominal aortic aneurysm (AAA) is rap-
idly gaining widespread clinical acceptance. Four commer-
cially available devices have been approved for general use.
Thoracic endografts are undergoing refinement and are not
yet available commercially, but some industry manufac-
tured investigational devices are being used to treat tho-
racic aortic aneurysm, dissection, and traumatic transec-
tion, with institution-specific investigational device
exemptions.
All of these devices are placed, at least in part, through
relatively large (18F-24F) sheaths, and must be positioned
appropriately within the aorta after the sheaths are passed
through access sites in the common femoral or iliac vessels.
With few exceptions, this type of access has traditionally
required open surgical exposure; the sheaths are passed
through an open arteriotomy after vascular clamps are
applied to control the vessels. In general, this process is safe,
but it must be performed by practitioners experienced in
open surgical technique. In many institutions open femoral
artery exposure mandates operating room availability and
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access is not without potential for complication.
With smaller access sheaths and with the development
of certain arterial closure devices, the complete percutane-
ous treatment of AAA with local anesthesia has become
feasible.1-4 In addition, percutaneous endoluminal treat-
ment of thoracic aortic disease is a viable option. Potential
advantages to percutaneous endograft deployment include
shorter procedure time, better patient acceptance, earlier
ambulation, and reduced risk for wound complications.
However, percutaneous sheath placement has its own
unique set of risks. For the past 3 years we have made an
attempt to place all infrarenal aortic devices and a select few
thoracic endovascular grafts with percutaneous techniques.
For the last 5 years we have maintained a prospective
database that has enabled us to compare and contrast
patients who have undergone placement of the bifurcated
Gore-Tex Excluder infrarenal endograft (W. L. Gore &
Associates) via percutaneous femoral access (PFA) with a
historic control group of patients who received the same
device via femoral artery cutdown (FAC) for treatment of
infrarenal AAA.
METHODS
Eighty-two consecutive patients who underwent endo-
vascular repair of an AAA at Northwestern Memorial Hos-
pital with the Gore Bifurcated Excluder endograft between
March 1999 and November 2003 were studied for evi-
dence of access-related complications. One hundred four-
teen other industry-manufactured devices (Guidant An-
cure, n 47; Medtronic AneuRx, n 65; Cook Zenith, n
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period, but because access technique was varied and few
patients were treated percutaneously, these patients are not
included in this review. Data were maintained prospectively
in an institution-specific database and in an alternate data-
base that has been kept for phase II of the Gore Excluder
Endograft Trial. Data were then reviewed retrospectively
from these prospectively maintained databases according to
guidelines indicated by the Northwestern University Med-
ical School institutional review board. Before November
2000, all patients underwent bilateral FAC for access to
deploy the endograft device. Over the next 3 years, from
November 2000 to November 2003, bilateral PFA was
attempted in all patients who underwent endovascular an-
eurysm repair with the Gore device. There were no specific
anatomic criteria on which the choice of access approach
was based other than those found in the instructions for use
of the Gore device. The decision for percutaneous treat-
ment was based solely on the temporal sequence in which
the patient was treated. Thirty-five patients underwent
bilateral FAC; 33 (94%) were men. Forty-seven patients
underwent bilateral PFA; 36 (77%) were men. Demo-
graphic data (age, weight, gender, AAA diameter) and
patient comorbid conditions (hypertension, coronary ar-
tery disease, stroke, diabetes mellitus, chronic obstructive
pulmonary disease, history of claudication, history of bleed-
ing disorders, renal failure, renal dialysis, current tobacco
use, or current steroid use) were analyzed.
All open femoral access was completed via small trans-
verse or oblique skin incisions, each about 4 cm long,
depending on patient body habitus. In performing open
access, care is taken to avoid lymphatic transection. Five to
6 cm of common femoral artery is exposed, heparin (5000
units) is administered, the vessels are clamped, an arteriot-
omy is created, and the appropriate sheath (12F  30 cm
[inner diameter, 0.162  0.004 in/–0 in; outer diameter,
0.185 0.002 in] or 18F 30 cm [inner diameter, 0.212
 0.002 in; outer diameter, .242 0.003 in/–.001 in]) is
passed through the opening under direct vision. When the
procedure is complete, the sheaths are removed, noncrush-
ing vascular clamps are reapplied, and the arteriotomy is
repaired with interrupted, fine monofilament suture.
Percutaneous access was performed through small stab
incisions with a pre-closure technique with a 10F Prostar
XL device (Perclose; Abbott).5 When performing the pro-
cedure percutaneously, arterial access is initiated with an
18-gauge needle. A standard J-wire is positioned in the
aorta, and a short 6F or 8F sheath is placed to pre-dilate the
access site. The sheath is then exchanged for the Prostar
device after a tract is cleared through the superficial soft-
tissue, down to the artery, using a hemostat or a finger. The
two Perclose 3-0 braided polyester sutures (one device) are
deployed before placement of the endograft deployment
sheaths (12F and 18F), and are left untied to rest on the
patient in radial orientation until after the endograft de-
ployment is complete. Patients undergoing percutaneous
access are also administered intravenous heparin for device
deployment, but in doses smaller than for FAC (1000-3000 units). When the procedure is complete, the sheaths
are removed while an assistant maintains proximal pressure
manually. The sutures are generously soaked with heparin-
ized saline solution and tied with a slipknot or a standard
surgeon’s knot while manual pressure is maintained. The
incisions are closed with a single suture or a Steri-Strip.
All patients in the two groups underwent physical ex-
amination and determination of ankle-brachial index pre-
operatively, postoperatively in the recovery room, and daily
during hospitalization. Outpatient follow-up consisted of
evaluation at 1, 6, and 12 months, and yearly thereafter. All
82 patients attended 1-month follow-up, in which they
underwent complete physical examination with determina-
tion of ankle-brachial index, plain abdominal radiography,
and abdominal computed tomography. Eight patients died
during follow-up, at 4, 5, 9, 14, 15, 19, 24, and 36 months,
of cancer (n  3), myocardial infarct (n  2), respiratory
failure (n 2), and hip fracture (n 1). Of 82 patients, 69
have attended 6-month follow-up.
Primary end points were any access-related complica-
tion, including infection, bleeding, arterial occlusion, arte-
rial emboli, arterial dissection, femoral neuropathy, lym-
phocele, leg pain, and leg edema. Secondary end points
included total operative time, total anesthesia time, type of
anesthesia used, estimated blood loss, transfusion require-
ment, time to first oral intake, time to first ambulation, and
hospital length of stay.
Data are expressed as mean  SEM. Differences be-
tween the two groups were determined with the Student t
test for normally distributed data, and the Mann-Whitney
rank sum test for nonparametric data. The 2 test or Fisher
exact test was used to compare nominal variables between
the two groups. Statistical significance was assumed at P 
.05. Statistical analysis was performed with Sigma Stat
(SPSS).
RESULTS
Mean aneurysm size was 5.7 cm in the FAC group and
6.0 cm in the PFA group. There were no significant differ-
ences with respect to demographic data or patient comor-
bid conditions between the two groups (Table I). In the
immediate postoperative period six patients (17%) in the
FAC cohort had access-related complications (Table II).
Complications included groin hematoma (n  2) and
femoral artery dissection, wound infection, femoral nerve
injury, and occlusion of a femoropopliteal artery bypass
graft (n  1 each). Three complications (dissection, groin
hematoma, graft occlusion) required returning the patient
to the operating room for further treatment.
In the PFA group, access-related complications oc-
curred more frequently (n 9, 19%) during the immediate
postoperative period compared with the FAC cohort (Ta-
ble II). All PFA complications were the result of hemor-
rhage (n  7) or arterial occlusion (n  2). Seven of the
nine complications (both arterial occlusions, five incidences
of hemorrhage) required immediate additional surgical in-
tervention. All seven complications were recognized and
ameliorated after the index operation before the patient was
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determine retrospectively whether the patients with periop-
erative events had particular risk factors that predisposed
them to complications.
During the index hospitalization some patients in each
group required blood transfusion (FAC group 4 [11%] vs
PFA group 6 [13%]). No access-related complications were
detected, and no apparent source of bleeding was identified
in more than half of these patients (FAC group 3 vs PFA
group 2). The remaining blood transfusions were required
secondary to access-related complications (FAC group 1 vs
PFA group 4). In the FAC cohort one patient required
transfusion secondary to blood loss incurred during repair







Pn % n %
No. of patients 35 47
Mean age (y) 74 75 .788
Patient weight (kg) .958
Mean 85.1 84.8
Range 56-149 50-159
Mean AAA size (cm) 5.7 6.0 .348
Male gender 33 94 36 77 .062
Hypertension 20 57 29 62 .850
Coronary artery
disease
20 57 27 57 .843
Cerebrovascular
disease
1 3 8 17 .094
Diabetes 7 20 9 19 .853
Renal dialysis 0 0 0 0 1.00
COPD 4 11 10 21 .381
Hypercholesterolemia 10 29 23 49 .103
Current tobacco use 8 23 6 13 .366
Bleeding disorder 0 0 0 0 1.00
Current steroid use 0 0 1 2 .882
History of
claudication
2 6 3 6 .733
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
disease.
Table II. Access complications detected during
immediate postoperative period
Bilateral femoral artery cutdown
(n  35)
Bilateral percutaneous femoral
access (n  47)




Groin hematoma* CFA bleed*
Wound infection CFA bleed*
Groin hematoma CFA bleed*




CFA, Common femoral artery.
*Required repeat operation.of a common femoral artery (CFA) dissection. In the PFA
cohort two patients received transfusions secondary to
blood loss incurred during thrombectomy of a CFA throm-
bosis. Two other patients in the PFA group received blood
transfusions because of bleeding of the CFA secondary to
failed pre-close technique. These numbers are too small to
make any generalizations or reach any statistical conclu-
sions.
An analysis of total operative time, anesthesia time,
estimated blood loss, time to first oral intake, time to
ambulation, and hospital length of stay was conducted
(Table III). Patients undergoing bilateral PFA had shorter
total operative time (PFA 139 minutes vs FAC 169 min-
utes; P .002), reduction in total in-room anesthesia time
(PFA 201 minutes vs FAC 225 minutes; P  .008), and
reduction in the use of general anesthesia (P  .001). No
significant differences were observed between the groups
with respect to estimated blood loss (PFA 459 mL vs FAC
389 mL; P .851), time to first oral intake (PFA 0.17 days
vs FAC 0.46 days; P .065), time to first ambulation (PFA
0.81 days vs FAC 0.80 days; P  .704), or overall hospital
length of stay (PFA 1.49 days vs FAC 1.89 days; P .411).
At 30-day follow-up, no additional access-related com-
plications were detected in the PFA group (0%). However,
there was a higher frequency of access-related complica-
tions in the FAC group; eight additional access-related
complications were detected in eight additional patients
(23%) in the FAC group (Table IV). Late complications
included femoral neuropathy (n 3), lymphocele (n 3),





































Spinal or epidural 3 9 13 27 .061
Local 0 0 6 13 .035
General 32 91 28 60 .003
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 1 Morasch et al 15scrotal edema (n 1), and wound infection (n 1). None
of these delayed access-related complications required ad-
ditional therapeutic intervention. At 6-month follow-up,
no additional access-related complications were detected in
either patient cohort; however, in the FAC group, at
6-month follow-up femoral neuropathy persisted in one
patient, as did lymphedema in the patient with the lympho-
cele at 1-month follow-up.
DISCUSSION
Endovascular treatment of infrarenal AAA has become
commonplace. As a viable alternative to open aneurysm
repair, this represents a major advancement, particularly in
the elderly and infirmed with AAAs that otherwise likely
would remain untreated. The advantages of complete per-
cutaneous endograft deployment are small but real when
compared with device deployment through open femoral
exposure. Percutaneous AAA repair requires special exper-
tise, however, and practitioners must become familiar with
particular arterial closure devices before they abandon open
access.
Arterial closure devices were originally developed for
use with smaller access sheaths. Bioabsorbable sponges
(Angio-Seal, Kensey-Nash), bovine collagen plugs (Vaso-
Seal VHD, Datascope), fibrin and thrombin procoagulant
glues (Duett, Vascular Solutions), and small suture-medi-
ated closure devices (Closer, Perclose; X-PRESS, X-Site
Medical) work relatively well after arterial puncture with 6F
and 8F sheaths.6-11 These adjuncts to manual pressure save
time, limit patient discomfort, and enable earlier patient
ambulation, but they cannot be used safely after arterial
access with 10F or larger sheaths.
Suture-mediated closure devices such as Prostar Plus
and Prostar XL (Perclose) can be used off-label to repair the
defect that remains after removal of the larger sheaths used
during endovascular AAA and thoracic aortic aneurysm
repair.1-4,12,13 Deployment of one or two of these devices
per femoral artery provides safe and secure arterial closure
through a simple stab incision in the groin.
Some real and some theoretic advantages to percutane-
ous aneurysm repair exist. In our experience, patients who
underwent percutaneous endograft deployment experi-
enced more rapid repair of the AAA, although it is quite
Table IV. Access complications detected at 1-month
follow-up
Bilateral femoral artery











Groin infectionpossible that this was related to the design of the study and
the learning curve associated with the Gore Excluder spe-
cifically as well as with endovascular AAA repair in general.
More patients received local or regional anesthesia, rather
than general anesthesia. We admit that this difference may
well be institution-specific, given that many others choose
regional anesthesia regardless of the access method. Also, in
theory, patients should proceed to ambulation sooner than
with open arterial access. Clearly, wound complications
noted after hospital discharge were less frequent after per-
cutaneous access compared with open arterial exposure.
Percutaneous access and arterial repair with suture-
mediated FAC devices is not risk-free. Device entrapment,
acute arterial thrombosis with limb ischemia, arterial injury,
suture breaks resulting in hemorrhage, arterial dissection,
suture infection, and pseudoaneurysm or arteriovenous
fistula formation have all been described after use of this
closure technique.14,15 In this review 15% (7 of 47) expe-
rienced immediate access site complications that required
urgent attention. Bleeding complications and acute arterial
occlusion were not uncommon, and often required treat-
ment with surgical exposure of the accessed artery immedi-
ately, before taking the patient from the operating suite.
When bleeding or ischemic complications occur, it is usu-
ally necessary to treat the problem immediately. Therefore
we continue to recommend that complete percutaneous
AAA repair be performed by surgeons and in an operating
room. Alternatively, percutaneous AAA repair can be un-
dertaken in a cardiac catheterization laboratory or an inter-
ventional radiology suite when both a surgeon and an
operating room are on standby for immediate assistance
and transfer if problems arise. The cost of maintaining an
open operating room and a surgeon on standby is not
insignificant. It also must be noted that this approach may
risk patient outcomes during the time lost to transport,
repeat preparation, and conversion to open exposure if
hemostasis is lost in a setting outside the operating room. It
is worth emphasizing that, while percutaneous access may
be most appealing to those performing these procedures
outside the operating suite, this is the precise setting in
which the risk for failure is highest.
Although Perclose suture infection was not observed in
any of our patients, this is a well-described complica-
tion.16-20 While the management of Perclose suture infec-
tion is beyond the scope of this article, suffice it to say this
is a vexing problem that requires specific vascular surgical
expertise. In this series there were no late Perclose compli-
cations despite close long-term patient observation.
We now generally consider all endograft patients to be
candidates for percutaneous repair. In our institution, all
patients who undergo AAA repair with the Gore Excluder
are taken to the operating room with the intent to repair the
aneurysm percutaneously. We have also treated a substan-
tial number of AAAs with other endograft types (Ancure,
Guidant; AneuRx, Medtronic; Zenith, Cook Inc) that re-
quire larger (24F) sheaths with percutaneous techniques.
In addition, we have successfully managed a handful of
patients who have undergone endograft repair of thoracic
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sections, with percutaneous access. Patients with very small,
severely calcified, or aneurysmal femoral arteries are not
ideal candidates for percutaneous repair, and must be
treated with caution. In patients who are morbidly obese
percutaneous treatment can also be more difficult, but
these patients may also reap the greatest benefit when the
approach is successful and an incision can be avoided.
CONCLUSION
Complete percutaneous treatment of AAA may have
some advantages over open femoral artery access, but it is
not free of risk. Certainly complete percutaneous treatment
of AAA can be performed with safety and efficacy equiva-
lent to open femoral artery access. Percutaneous treatment
of AAA can be attempted in most patients, but should be
performed in a sterile environment or where open arterial
access can be obtained rapidly if required.
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